Ergot Alkaloids (Migraine) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 47 Pages
|麥角生物鹼(用作偏頭痛治療藥):市場預測與分析 Ergot Alkaloids (Migraine) - Forecast and Market Analysis to 2023|
|出版日期: 2014年03月31日||內容資訊: 英文 47 Pages||
麥角生物鹼是市場上第一個供給的偏頭痛特異療法藥物。雖然純麥角生物鹼在1920年第一次被分離出來，但1925年才成功皮下注射治療嚴重難治型偏頭痛(Rothlin, 1955; Stoll, 1965)。這10年來，許多研究員將麥角胺作為偏頭痛治療藥進行各種研究。可使血管收縮的特性強化了研究者對於「偏頭痛的發作是血管造成的」這個假說的確信。
The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
The Ergot Alkaloids were the very first anti-migraine-specific therapy class to reach the market. The first pure ergot alkaloid was isolated in 1920, but only in 1925 was ergotamine used to successfully treat a case of severe and intractable migraine via subcutaneous injection (Rothlin, 1955; Stoll, 1965). Over the following decades, ergotamine's use as a migraine treatment was investigated by various researchers and its potent vasoconstriction properties reinforced the belief that migraine had a vascular origin.